Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genprex Inc (NQ: GNPX ) 2.150 -0.100 (-4.44%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Genprex Inc < Previous 1 2 3 4 Next > Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX) September 04, 2024 Via Get News Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX) August 22, 2024 Via Get News Topics Intellectual Property Exposures Intellectual Property Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX) May 14, 2024 Via Get News New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX) May 13, 2024 Via Get News BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events May 01, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy April 02, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering March 25, 2024 Via Investor Brand Network Exposures Product Safety TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering March 25, 2024 Via Investor Brand Network Exposures Product Safety TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering March 19, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering March 19, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio March 13, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting March 06, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications February 07, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications February 07, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference February 06, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient February 05, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient February 05, 2024 Via Investor Brand Network Exposures Product Safety Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer November 22, 2023 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023 November 01, 2023 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event October 20, 2023 Via Investor Brand Network BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference October 04, 2023 Via Investor Brand Network Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC September 21, 2023 From Genprex, Inc. Via GlobeNewswire BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program September 20, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation September 20, 2023 Via Investor Brand Network Exposures Product Safety Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation September 20, 2023 EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations September 15, 2023 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference September 07, 2023 Via Investor Brand Network Exposures Product Safety Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline September 05, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’ September 01, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial August 30, 2023 Via Investor Brand Network Exposures Product Safety < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
